

Adv. Gouri S. Lokhande (Ghanwat)
Office No. 10, Om Ganesh Market Opp. Brannha Hotel Lane,
Manikwarg, Sinhaged Road, Pune - 411 051. Mob. 9049003203

Address –Can Fin Homes Ltd; Chakan Branch, Office
No.171, First Floor, Jadhav Commercial Centre, Opp. St
Stand, Chakan Shikrapur Rd, Chakan - 410 501.
Telephone : 02135 - 249230
Email: chakan@canfinhomes.com
CIN : L85110KA1987PLC008699

DEMAND NOTICE

on and Reconstruction of Financial Assets and Enforcement of Security with Rule 3(1) of the Security Interest (Enforcement) Rules, 2002 (Rules)

Authorized Officer of Can Fin Homes Ltd., under SARFAESI Act and in exercise of power conferred by Rule 3, issued Demand Notice under Section 13(2) of the said Act, calling upon the Borrower (hereinafter referred to as the "said Borrowers"), to repay the amount due to the lender.

The demand notice is hereby served on you by registered post, by the date of receipt of the postal authorities, as per details given below.

The said Borrowers have delivered by the postal authorities / have not been duly acknowledged by the said Borrowers, the abundant caution effecting this publication of the demand notice (as per the provisions of the said Act), has therefore, caused these Notices to be pasted on the premises of the last mentioned Borrowers.

As per the said Act,

the following assets have been mortgaged to the Company by the respective

with	Amount claimed as per Demand Notice*	Description of the Secured Asset	Date of NPA
(Borrower) M/s. Can Fin Homes Ltd. Dist:	Rs.2707958/- (Twenty Seven Lakh Seventy Seven Thousand Nine Hundred Fifty Eight Only) As on 04.09.2026	Gat No-2036, Milikat Ziiraimala, Bhordara Road, Aadash Nagar, Colony No-01, Chakan, Tal-Khed, Dist- Pune- 410501. Four Boundaries: NORTH : Property By Mr. Namedev Hulgutte SOUTH : Property By Mr. Vinod Patil EAST : Property By Mr. Vishal Naikwadi WEST : Internal Road 1ft	29/08/2026

* The above rates as agreed from the date mentioned above till date of payment.

The said Borrowers have paid amount with contracted rate of interest thereon within 60 days from the date of the undersigned will be constrained to initiate action under SARFAESI Act to recover the dues of the said Borrowers. In case of non-payment of the said Borrowers, the attention of borrowers / guarantors is invited to provisions of Section 13(B) of the Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002.

Sd/-
Authorised Officer
Can Fin Homes Ltd.




THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF IBERIA PHARMACEUTICALS INDIA LIMITED ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGE") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENT) REGULATIONS, 2018 AS AMENDED ("SEBI ICDR REGULATIONS")

Please scan the QR Code to view the
DRHP and Draft Abridged Prospectus

IBERIA
PHARMACEUTICALS

IBERIA PHARMACEUTICALS INDIA LIMITED

(Previously Known as Iberia Pharmaceuticals India Private Limited)

CIN: U21002DL2013PLC250040

Our Company was originally incorporated as 'Satnam Medical Agencies Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 30, 2013, issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, the name of our Company was changed from 'Satnam Medical Agencies Private Limited' to 'Iberia Pharmaceuticals India Private Limited' by way of shareholders' resolution dated August 11, 2023. Consequently, a certificate of incorporation pursuant to change of name, dated September 18, 2023, was issued to the Company by the Registrar of Companies, Delhi. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on April 8, 2024, and consequently, a fresh certificate of incorporation dated July 15, 2024 was issued by the Registrar of Companies, Central Processing Centre ("CPC") to our Company under its present name i.e., 'Iberia Pharmaceuticals India Limited'. Our Company's Corporate Identity Number is U21002DL2013PLC250040.

Registered Office: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, Delhi, India, 110077

Corporate Office: Unit No. 304-305, 3rd Floor Tower-B, Global Business Park MG Road, DLF QE, Gurgaon, Haryana, India, 122002

Tel: +91 9319728265, **Fax:** N.A., **Website:** www.iberiapharmaceuticals.com; **E-mail:** cs@iberiapharmaceuticals.com, **Company Secretary and Compliance Officer:** Mr. Raj Kumar

OUR PROMOTERS: MR. NITIN JAIN, MR. RISHABH JAIN, MR. SAURAV OJHA & MRS. SHIVANI JAIN

INITIAL PUBLIC OFFERING OF UP TO 64,75,560 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF IBERIA PHARMACEUTICALS INDIA LIMITED (OUR "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING UP TO ₹ [•] LAKHS ("THE ISSUE"). THE ISSUE SHALL CONSIST OF [•]% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF THE COMPANY.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10 EACH AND THE ISSUE PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER AND WILL BE ADVERTISED IN ALL EDITIONS OF THE ENGLISH NATIONAL DAILY NEWSPAPER [•]. ALL EDITIONS OF THE HINDI NATIONAL DAILY NEWSPAPER [•] AND [•] EDITION OF [•] (HINDI ALSO BEING THE REGIONAL LANGUAGE OF THE STATE WHEREIN THE REGISTERED OFFICE OF OUR COMPANY IS LOCATED) EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO STOCK EXCHANGES FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process and is in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein in terms of Regulation 32(1) of the SEBI ICDR Regulations, not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs"), and such portion, the "QIB Portion" provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which 33.33% shall be available for allocation to domestic Mutual Funds and 6.67% shall be reserved for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price"), in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Bidders out of which (a) one-third of such portion shall be reserved for applicants with application size of more than 200,000 and upto 10,00,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than 10,00,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders (RIBs) in accordance with the SEBI ICDR Regulations ("Retail Portion"), subject to valid Bids being received from them at or above the Issue Price. Further, all potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid amount will be blocked by the SCSBs or the Sponsor Bank, as applicable, to participate in the Issue. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 337 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that the Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other consideration, to make an initial public offering of its Equity Shares pursuant to the Issue and has filed the DRHP and the Draft Abridged Prospectus on September 05, 2026 with the Stock Exchanges and Securities and Exchange Board of India (SEBI). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it along with the Draft Abridged Prospectus on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com, on the website of the Company at www.iberiapharmaceuticals.com; and on the websites of the Book Running Lead Managers ("BRLM"), i.e. Turnaround Corporate Advisors Private Limited at www.tacgroup.in. The Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Issue on or before 5.00 P.M. on the 21st day from the date of publication of this public announcement.

Investments in equity and equity related securities involve a degree of risk and Bidders should not invest any funds in the Issue unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, Bidders must rely on their own examination of the Company and the Issue. Including the risks involved. The Equity Shares in the Issue have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Special attention of the Bidders is invited to 'Risk factor' beginning on page 23 of the DRHP. Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges. For details of the share capital and capital structure and the names of the signatories of the Memorandum of Association and the number of shares subscribed by them of the Company, please see the section titled "Capital Structure" on page 88 of the DRHP. The liability of the members of the Company is limited by their shares. For details of the main objects of the Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 244 of the DRHP.								
<table border="1"> <thead> <tr> <th>BOOK RUNNING LEAD MANAGER</th><th>REGISTRAR TO THE ISSUE</th><th>COMPANY SECRETARY AND COMPLIANCE OFFICER</th></tr> </thead> <tbody> <tr> <td>  TURNAROUND CORPORATE ADVISORS PRIVATE LIMITED Address: 614, Vishwadeep Building, Plot No. 4 District Centre, Janakpuri A-3, West Delhi- 110058, India Telephone: +91 8287356934 Email: iberia.ipo@Turnaroundmb.com Website: www.tcagroup.in Contact Person: Rajveer Singh SEBI Registration Number: INM000012290 </td><td>  BIGSHARE SERVICES PRIVATE LIMITED Address: Office No. S-62, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai -400093 Telephone No: +91 22 62638200 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Investor grievance: investor@bigshareonline.com Contact Person: Rajesh Kumawat SEBI Registration No.: INR000001385 </td><td>  Raj Kumar Address: Property No.4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, Delhi, India 110077 Telephone: +91 9319728265 Email: cs@iberiapharmaceuticals.com Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems. Such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc. </td></tr> </tbody> </table>			BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER	 TURNAROUND CORPORATE ADVISORS PRIVATE LIMITED Address: 614, Vishwadeep Building, Plot No. 4 District Centre, Janakpuri A-3, West Delhi- 110058, India Telephone: +91 8287356934 Email: iberia.ipo@Turnaroundmb.com Website: www.tcagroup.in Contact Person: Rajveer Singh SEBI Registration Number: INM000012290	 BIGSHARE SERVICES PRIVATE LIMITED Address: Office No. S-62, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai -400093 Telephone No: +91 22 62638200 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Investor grievance: investor@bigshareonline.com Contact Person: Rajesh Kumawat SEBI Registration No.: INR000001385	 Raj Kumar Address: Property No.4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, Delhi, India 110077 Telephone: +91 9319728265 Email: cs@iberiapharmaceuticals.com Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems. Such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.
BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER						
 TURNAROUND CORPORATE ADVISORS PRIVATE LIMITED Address: 614, Vishwadeep Building, Plot No. 4 District Centre, Janakpuri A-3, West Delhi- 110058, India Telephone: +91 8287356934 Email: iberia.ipo@Turnaroundmb.com Website: www.tcagroup.in Contact Person: Rajveer Singh SEBI Registration Number: INM000012290	 BIGSHARE SERVICES PRIVATE LIMITED Address: Office No. S-62, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai -400093 Telephone No: +91 22 62638200 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Investor grievance: investor@bigshareonline.com Contact Person: Rajesh Kumawat SEBI Registration No.: INR000001385	 Raj Kumar Address: Property No.4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, Delhi, India 110077 Telephone: +91 9319728265 Email: cs@iberiapharmaceuticals.com Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems. Such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.						
All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.								
For IBERIA PHARMACEUTICALS INDIA LIMITED On Behalf of the Board of Directors Sd/- Raj Kumar Company Secretary and Compliance Officer								
Place: Delhi Date: September 05, 2026								
Disclaimer: Iberia Pharmaceuticals India Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on September 05, 2026. The DRHP along with the Draft Abridged Prospectus is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.iberiapharmaceuticals.com; and on the websites of the Book Running Lead Managers ("BRLM"), i.e. Turnaround Corporate Advisors Private Limited at www.tcagroup.com. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 23 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S), except pursuant to exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transaction in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sale occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.								